Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Cell-free DNA analysis in healthy individuals by next-generation sequencing: a proof of concept and technical validation study.

Alborelli I, Generali D, Jermann P, Cappelletti MR, Ferrero G, Scaggiante B, Bortul M, Zanconati F, Nicolet S, Haegele J, Bubendorf L, Aceto N, Scaltriti M, Mucci G, Quagliata L, Novelli G.

Cell Death Dis. 2019 Jul 11;10(7):534. doi: 10.1038/s41419-019-1770-3.

2.

Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer.

Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, Nobili S, Sobhani N.

Cancer Chemother Pharmacol. 2019 Jun 11. doi: 10.1007/s00280-019-03887-2. [Epub ahead of print] Review.

PMID:
31187168
3.

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Cazzaniga ME, Biganzoli L, Cortesi L, De Placido S, Donadio M, Fabi A, Ferro A, Generali D, Lorusso V, Milani A, Montagna E, Munzone E, Orlando L, Pizzuti L, Simoncini E, Zamagni C, Pappagallo GL; “Metronomic Chemotherapy in Advanced Breast Cancer” Study Group.

Onco Targets Ther. 2019 Apr 23;12:2989-2997. doi: 10.2147/OTT.S189163. eCollection 2019.

4.

Avelumab in gastric cancer.

Roviello G, D'Angelo A, Generali D, Pittacolo M, Ganzinelli M, Iezzi G, Manzini N, Sobhani N.

Immunotherapy. 2019 Jun;11(9):759-768. doi: 10.2217/imt-2019-0011. Epub 2019 May 6.

PMID:
31060469
5.

Efficacy of extended aromatase inhibitors for hormone-receptor-positive breast cancer: A literature-based meta-analysis of randomized trials.

Corona SP, Roviello G, Strina C, Milani M, Madaro S, Zanoni D, Allevi G, Aguggini S, Cappelletti MR, Francaviglia M, Azzini C, Cocconi A, Sirico M, Bortul M, Zanconati F, Giudici F, Rosellini P, Meani F, Pagani O, Generali D.

Breast. 2019 Aug;46:19-24. doi: 10.1016/j.breast.2019.04.004. Epub 2019 Apr 25.

PMID:
31051411
6.

Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.

Sobhani N, D'Angelo A, Pittacolo M, Roviello G, Miccoli A, Corona SP, Bernocchi O, Generali D, Otto T.

Cells. 2019 Apr 6;8(4). pii: E321. doi: 10.3390/cells8040321. Review.

7.

Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma.

Sobhani N, Roviello G, Pivetta T, Ianza A, Bonazza D, Zanconati F, Giudici F, Bottin C, Corona SP, Guglielmi A, Rizzardi C, Milione M, Cortale M, Confalonieri M, Generali D.

Mol Biol Rep. 2019 Jun;46(3):2713-2720. doi: 10.1007/s11033-019-04715-9. Epub 2019 Mar 6.

PMID:
30840203
8.

New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When.

Roviello G, Generali D.

Clin Genitourin Cancer. 2019 Jun;17(3):e534-e535. doi: 10.1016/j.clgc.2019.01.020. Epub 2019 Feb 6. No abstract available.

PMID:
30827924
9.

Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue.

Roviello G, Generali D, Ianza A.

Immunotherapy. 2019 Apr;11(5):365-368. doi: 10.2217/imt-2018-0204. No abstract available.

10.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Cristofanilli M, Pierga JY, Reuben J, Rademaker A, Davis AA, Peeters DJ, Fehm T, Nolé F, Gisbert-Criado R, Mavroudis D, Grisanti S, Giuliano M, Garcia-Saenz JA, Stebbing J, Caldas C, Gazzaniga P, Manso L, Zamarchi R, de Lascoiti AF, De Mattos-Arruda L, Ignatiadis M, Cabel L, van Laere SJ, Meier-Stiegen F, Sandri MT, Vidal-Martinez J, Politaki E, Consoli F, Generali D, Cappelletti MR, Diaz-Rubio E, Krell J, Dawson SJ, Raimondi C, Rutten A, Janni W, Munzone E, Carañana V, Agelaki S, Almici C, Dirix L, Solomayer EF, Zorzino L, Darrigues L, Reis-Filho JS, Gerratana L, Michiels S, Bidard FC, Pantel K.

Crit Rev Oncol Hematol. 2019 Feb;134:39-45. doi: 10.1016/j.critrevonc.2018.12.004. Epub 2018 Dec 19. Review.

PMID:
30771872
11.

Current status of PI3K-mTOR inhibition in hormone-receptor positive, HER2-negative breast cancer.

Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B.

World J Clin Oncol. 2018 Dec 20;9(8):172-179. doi: 10.5306/wjco.v9.i8.172.

12.

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri V.

Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431. eCollection 2018 Nov 30.

13.

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit.

Triulzi T, Regondi V, De Cecco L, Cappelletti MR, Di Modica M, Paolini B, Lollini PL, Di Cosimo S, Sfondrini L, Generali D, Tagliabue E.

Br J Cancer. 2018 Dec;119(12):1487-1494. doi: 10.1038/s41416-018-0318-0. Epub 2018 Nov 27.

14.

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri On Behalf Of The Eva Study Group V.

Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213. eCollection 2018 Oct 2.

15.

Pertuzumab therapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer.

Roviello G, Generali D.

Lancet Oncol. 2018 Oct;19(10):1270-1272. doi: 10.1016/S1470-2045(18)30512-6. Epub 2018 Sep 11. No abstract available.

PMID:
30217673
16.

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Cazzaniga M, Verusio C, Ciccarese M, Fumagalli A, Sartori D, Valerio MR, Ancona C, Airoldi M, Moretti G, Ficorella C, Arcangeli V, Diodati L, Zambelli A, Febbraro A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L, La Verde N, Bianchi G, Artale S, Blasi L, Piezzo M, Atzori F, Turletti A, Benedetto C, Cursano MC, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A, Frassoldati A, Scavelli C, Clivio L, Torri On Behalf Of The Eva Study Group V.

Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874. eCollection 2018 Aug 7. Erratum in: Oncotarget. 2018 Oct 2;9(77):34639-34640. Valerio, Maria Rosario [added]. Oncotarget. 2018 Nov 30;9(94):36720-36721.

17.

Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience.

Roviello G, Generali D, Aieta M, Bonetta A.

Rep Pract Oncol Radiother. 2018 Jul-Aug;23(4):298-299. doi: 10.1016/j.rpor.2018.06.001. Epub 2018 Jul 17.

18.

Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.

Sobhani N, Generali D, D'Angelo A, Aieta M, Roviello G.

Invest New Drugs. 2018 Dec;36(6):1133-1137. doi: 10.1007/s10637-018-0653-2. Epub 2018 Aug 7. Review.

PMID:
30083960
19.

Familial aggregation of gastric cancer with microsatellite instability.

Polom K, Marrelli D, Voglino C, Roviello G, De Franco L, Vindigni C, Generali D, Roviello F.

Acta Chir Belg. 2018 Oct;118(5):287-293. doi: 10.1080/00015458.2017.1379789. Epub 2018 Aug 3.

PMID:
30071769
20.

Current Status of Fibroblast Growth Factor Receptor-Targeted Therapies in Breast Cancer.

Sobhani N, Ianza A, D'Angelo A, Roviello G, Giudici F, Bortul M, Zanconati F, Bottin C, Generali D.

Cells. 2018 Jul 15;7(7). pii: E76. doi: 10.3390/cells7070076. Review.

21.

PIK3CA mutation in gastric cancer and the role of microsatellite instability status in mutations of exons 9 and 20 of the PIK3CA gene.

Polom K, Marrelli D, Roviello G, Pascale V, Voglino C, Vindigni C, Generali D, Roviello F.

Adv Clin Exp Med. 2018 Jul;27(7):963-969. doi: 10.17219/acem/70795.

22.

Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts.

Guffanti F, Fratelli M, Ganzinelli M, Bolis M, Ricci F, Bizzaro F, Chilà R, Sina FP, Fruscio R, Lupia M, Cavallaro U, Cappelletti MR, Generali D, Giavazzi R, Damia G.

Oncotarget. 2018 May 15;9(37):24707-24717. doi: 10.18632/oncotarget.25185. eCollection 2018 May 15.

23.

Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer.

Roviello G, Corona SP, Multari AG, Paganini G, Chiriacò G, Conca R, Petrioli R, Generali D, Rosellini P, Aieta M.

Oncotarget. 2018 Apr 27;9(32):22332-22339. doi: 10.18632/oncotarget.24900. eCollection 2018 Apr 27.

24.

Lenvatinib for the treatment of renal cell carcinoma.

Roviello G, Corona SP, Bozza G, Aieta M, Generali D, Rodriquenz MG, Mileo AM, Imperatori M, Ianza A, Conca R, Sobhani N.

Expert Opin Investig Drugs. 2018 May;27(5):507-512. doi: 10.1080/13543784.2018.1472235. Epub 2018 May 14. Review.

PMID:
29718721
25.

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K.

J Natl Cancer Inst. 2018 Jun 1;110(6):560-567. doi: 10.1093/jnci/djy018.

PMID:
29659933
26.

Cell-free DNA integrity for the monitoring of breast cancer: Future perspectives?

Sobhani N, Generali D, Zanconati F, Bortul M, Scaggiante B.

World J Clin Oncol. 2018 Apr 10;9(2):26-32. doi: 10.5306/wjco.v9.i2.26. Review.

27.

The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

Cretella D, Ravelli A, Fumarola C, La Monica S, Digiacomo G, Cavazzoni A, Alfieri R, Biondi A, Generali D, Bonelli M, Petronini PG.

J Exp Clin Cancer Res. 2018 Mar 27;37(1):72. doi: 10.1186/s13046-018-0741-3. No abstract available.

28.

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2- advanced breast cancer.

Corona SP, Generali D.

Drug Des Devel Ther. 2018 Feb 16;12:321-330. doi: 10.2147/DDDT.S137783. eCollection 2018. Review.

29.

Is the fatigue an adverse event of the second generation of hormonal therapy? Data from a literature-based meta-analysis.

Roviello G, Generali D.

Med Oncol. 2018 Jan 31;35(3):29. doi: 10.1007/s12032-018-1081-z.

PMID:
29387974
30.

The prognostic value of PI3K mutational status in breast cancer: A meta-analysis.

Sobhani N, Roviello G, Corona SP, Scaltriti M, Ianza A, Bortul M, Zanconati F, Generali D.

J Cell Biochem. 2018 Jun;119(6):4287-4292. doi: 10.1002/jcb.26687. Epub 2018 Mar 1.

31.

Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.

Generali D, Corona SP, Pusztai L, Rouzier R, Allevi G, Aguggini S, Milani M, Strina C, Frati A.

J Cancer Res Clin Oncol. 2018 Mar;144(3):601-606. doi: 10.1007/s00432-017-2574-4. Epub 2018 Jan 17.

PMID:
29344722
32.

Curcumin as an Adjunct Therapy and microRNA Modulator in Breast Cancer.

Norouzi S, Majeed M, Pirro M, Generali D, Sahebkar A.

Curr Pharm Des. 2018;24(2):171-177. doi: 10.2174/1381612824666171129203506.

PMID:
29189128
33.

Ado-trastuzumab emtansine (T-DM1) in HER2+ advanced breast cancer patients: does pretreatment with pertuzumab matter?

Fabi A, Giannarelli D, Moscetti L, Santini D, Zambelli A, Laurentiis M, Caruso M, Generali D, Valle E, Leonardi V, Cannita K, Arpino G, Filippelli G, Ferretti G, Giampaglia M, Montemurro F, Nisticò C, Gasparro S, Cognetti F.

Future Oncol. 2017 Dec;13(30):2791-2797. doi: 10.2217/fon-2017-0336. Epub 2017 Nov 28.

PMID:
29182361
34.

Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?

Corona SP, Roviello G, Strina C, Milani M, Allevi G, Aguggini S, Zanoni D, Generali D.

Future Oncol. 2017 Nov;13(27):2473-2477. doi: 10.2217/fon-2017-0272. Epub 2017 Nov 10.

PMID:
29121807
35.

Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.

Milani M, Venturini S, Bonardi S, Allevi G, Strina C, Cappelletti MR, Corona SP, Aguggini S, Bottini A, Berruti A, Jubb A, Campo L, Harris AL, Gatter K, Fox SB, Generali D, Roviello G.

Oncotarget. 2017 Aug 14;8(45):78870-78881. doi: 10.18632/oncotarget.20239. eCollection 2017 Oct 3.

36.

Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.

Roviello G, Andre F, Venturini S, Pistilli B, Curigliano G, Cristofanilli M, Rosellini P, Generali D.

Eur J Cancer. 2017 Nov;86:257-265. doi: 10.1016/j.ejca.2017.09.018. Epub 2017 Oct 19. Review.

PMID:
29055841
37.

Advances in systemic therapy for malignant mesothelioma: future perspectives.

Sobhani N, Corona SP, Bonazza D, Ianza A, Pivetta T, Roviello G, Cortale M, Guglielmi A, Zanconati F, Generali D.

Future Oncol. 2017 Oct;13(23):2083-2101. doi: 10.2217/fon-2017-0224. Epub 2017 Oct 6. Review.

PMID:
28984470
38.

Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.

Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, Cannita K, Carbognin L, Ciccarese M, Rossello R, Arpino G, Leonardi V, Montemurro F, La Verde N, Generali D, Zambelli A, Scandurra G, Russillo M, Paris I, D'Ottavio AM, Filippelli G, Giampaglia M, Stani S, Fabbri A, Alesini D, Cianniello D, Giannarelli D, Cognetti F.

Oncotarget. 2017 Mar 18;8(38):64481-64489. doi: 10.18632/oncotarget.16373. eCollection 2017 Sep 8.

39.

Bevacizumab in small cell lung cancer.

Roviello G, Sobhani N, Generali D.

Ann Transl Med. 2017 Sep;5(17):361. doi: 10.21037/atm.2017.06.44. No abstract available.

40.
41.

Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer.

Roviello G, Corona SP, Bonetta A, Cappelletti MR, Generali D.

Onco Targets Ther. 2017 Jul 31;10:3811-3815. doi: 10.2147/OTT.S143020. eCollection 2017.

42.

Isolated Testicular Metastasis from Prostate Cancer.

Bonetta A, Generali D, Corona SP, Cancarini G, Brenna SG, Pacifico C, Roviello G.

Am J Case Rep. 2017 Aug 14;18:887-889.

43.

Influence of Prior Tyrosine Kinase Inhibitor on Survival for Patients with Metastatic Renal Cell Carcinoma Treated with Nivolumab or Cabozantinib: Data from a Literature-based Meta-analysis.

Roviello G, Generali D.

Eur Urol. 2017 Dec;72(6):1027-1028. doi: 10.1016/j.eururo.2017.07.019. Epub 2017 Jul 29. No abstract available.

PMID:
28760645
44.

Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma.

Sobhani N, Roviello G, Corona SP, Ianza A, Zanconati F, Generali D.

Lung Cancer. 2017 Dec;114:103-105. doi: 10.1016/j.lungcan.2017.07.027. Epub 2017 Jul 24. No abstract available.

PMID:
28757047
45.

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.

Cazzaniga ME, Airoldi M, Arcangeli V, Artale S, Atzori F, Ballerio A, Bianchi GV, Blasi L, Campidoglio S, Ciccarese M, Cursano MC, Piezzo M, Fabi A, Ferrari L, Ferzi A, Ficorella C, Frassoldati A, Fumagalli A, Garrone O, Gebbia V, Generali D, La Verde N, Maur M, Michelotti A, Moretti G, Musolino A, Palumbo R, Pistelli M, Porpiglia M, Sartori D, Scavelli C, Schirone A, Turletti A, Valerio MR, Vici P, Zambelli A, Clivio L, Torri V; on behalf of; EVA Study Group.

Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

PMID:
28711793
46.

PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy.

Sobhani N, Generali D, Roviello G.

EBioMedicine. 2017 Aug;22:18-19. doi: 10.1016/j.ebiom.2017.07.003. Epub 2017 Jul 5. No abstract available.

47.

Cyclin dependent kinase 4 and 6 inhibitors as novel therapeutic agents for targeted treatment of malignant mesothelioma.

Sobhani N, Corona SP, Zanconati F, Generali D.

Genes Cancer. 2017 Mar;8(3-4):495-496. doi: 10.18632/genesandcancer.138.

48.

Erratum to: Advances in systemic therapy for metastatic breast cancer: future perspectives.

Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D.

Med Oncol. 2017 Jul;34(7):130. doi: 10.1007/s12032-017-0989-z. No abstract available.

PMID:
28616710
49.

Advances in systemic therapy for metastatic breast cancer: future perspectives.

Corona SP, Sobhani N, Ianza A, Roviello G, Mustacchi G, Bortul M, Zanconati F, Generali D.

Med Oncol. 2017 Jul;34(7):119. doi: 10.1007/s12032-017-0975-5. Epub 2017 May 19. Review. Erratum in: Med Oncol. 2017 Jul;34(7):130.

PMID:
28526922
50.

Enteric-coated and highly standardized cranberry extract reduces antibiotic and nonsteroidal anti-inflammatory drug use for urinary tract infections during radiotherapy for prostate carcinoma.

Bonetta A, Roviello G, Generali D, Zanotti L, Cappelletti MR, Pacifico C, Di Pierro F.

Res Rep Urol. 2017 Apr 26;9:65-69. doi: 10.2147/RRU.S133538. eCollection 2017.

Supplemental Content

Loading ...
Support Center